Table 2.
Reductions in Plasma Proteins Are Associated with Reductions in ALT and VAT and Increases in IGF-1
| Change in ALT | Change in VAT | Change in IGF-1 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| r | β* | P | r | β* | P | r | β* | P | |
| Δ CCL3 | 0.58 | 0.22 | <.0001 | 0.31 | 0.02 | .05 | -0.30 | -0.02 | .05 |
| Δ CCL4 | 0.31 | 0.10 | .046 | 0.25 | 0.02 | .11 | -0.36 | -0.02 | .02 |
| Δ MCP-4 | 0.40 | 0.18 | .008 | 0.06 | 0.005 | .71 | -0.21 | -0.01 | .17 |
| Δ CXCL8 (IL8) | 0.39 | 0.20 | .01 | 0.00 | 0.0001 | .99 | -0.24 | -0.02 | .12 |
| Δ IL10 | 0.42 | 0.14 | .005 | -0.02 | -0.001 | .92 | -0.41 | -0.02 | .006 |
| Δ CSF-1 | 0.56 | 0.09 | <.0001 | 0.10 | 0.003 | .53 | -0.38 | -0.01 | .01 |
| Δ CD8A | 0.50 | 0.17 | .0007 | 0.19 | 0.01 | .23 | -0.31 | -0.02 | .04 |
| Δ CRTAM | 0.26 | 0.12 | .09 | 0.39 | 0.04 | .01 | -0.46 | -0.03 | .002 |
| Δ GZMA | -0.01 | -0.004 | .96 | 0.16 | 0.02 | .31 | -0.09 | -0.007 | .56 |
| Δ ADGRG1 | 0.57 | 0.26 | <.0001 | 0.18 | 0.02 | .24 | -0.42 | -0.03 | .005 |
| Δ ARG1 | 0.21 | 0.22 | .17 | 0.52 | 0.11 | .0004 | -0.14 | -0.02 | .35 |
| Δ Gal-9 | 0.53 | 0.11 | .0003 | 0.39 | 0.02 | .01 | -0.30 | -0.01 | .05 |
| Δ HGF | 0.51 | 0.14 | .0005 | 0.26 | 0.01 | .09 | -0.25 | -0.01 | .10 |
r- and P-values for Pearson correlation of changes over 12 months, and β-estimate (n = 43 individuals for whom baseline and 12-month data were available).
Abbreviations: ADGRG1, adhesion G-protein coupled receptor G1; ALT, alanine aminotransferase; ARG1, arginase-1; CCL3, C-C motif chemokine 3; CCL4, C-C motif chemokine 4; CD8A, T-cell surface glycoprotein CD8 alpha chain; CRTAM, cytotoxic and regulatory T-cell molecule; CSF-1, macrophage colony-stimulating factor 1; CXCL8, interleukin-8; Gal-9, galectin-9; GZMA, granzyme A; HGF, hepatocyte growth factor; IGF-1, insulin-like growth factor 1; IL10, interleukin 10; MCP-4, C-C motif chemokine 13, also known as monocyte chemoattractant protein-4; VAT, visceral adipose tissue.
* β-estimate describes the Log2 fold change in plasma protein for each 10 U/L change in ALT, each 10 cm2 change in VAT, or each 10 ng/mL change in IGF-1.